Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

691
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
691
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

3.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
3.0K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

74.6K
Overview
74.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liver-X-receptor agonism enhances T cell priming and activation to promote anti-tumor immunity.

The Journal of experimental medicine·2026
Same author

A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells.

Cancer research·2026
Same author

Carboxylic Acid Bioisosteres of Creatine as Novel and Selective Substrate Competitive Inhibitors of the Creatine Transporter SLC6A8.

Journal of medicinal chemistry·2026
Same author

MED1 IDR deacetylation controls stress responsive genes through RNA Pol II recruitment.

Nature chemical biology·2025
Same author

Tumor Genotype Dictates Mitochondrial and Immune Vulnerabilities in Liver Cancer.

bioRxiv : the preprint server for biology·2025
Same author

Conserved genetic basis for microbial colonization of the gut.

Cell·2025
Same journal

Targeting cholesterol esterification sensitizes liver cancer to CD8<sup>+</sup> T cell attack by impairing metabolic and redox resilience.

Immunity·2026
Same journal

Brain endothelial cells orchestrate a neuroprotective antiviral state in the CNS in response to peripheral viral pattern sensing.

Immunity·2026
Same journal

Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors.

Immunity·2026
Same journal

B cell-derived type I interferon sustains T cell functionality upon strong TCR stimulation during chronic infection.

Immunity·2026
Same journal

Lactate binds and inhibits the innate immune sensor STING to promote tumor immune evasion.

Immunity·2026
Same journal

Antibody binding geometry and affinity control inhibitory hFcγRIIB receptor signaling.

Immunity·2026
See all related articles

Related Experiment Video

Updated: Sep 27, 2025

Generation of a RIP1 Knockout U937 Cell Line Using the CRISPR-Cas9 System
08:15

Generation of a RIP1 Knockout U937 Cell Line Using the CRISPR-Cas9 System

Published on: April 11, 2025

462

RIP(K)ing away immunotherapy resistance.

Mira A Patel1, Sohail F Tavazoie1

  • 1Laboratory of Systems Cancer Biology, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.

Immunity
|April 13, 2022
PubMed
Summary
This summary is machine-generated.

Interferon signaling drives resistance to immune checkpoint blockade therapy. Researchers found RIPK1, an interferon-stimulated gene, significantly impacts immunotherapy resistance.

More Related Videos

Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells
09:15

Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells

Published on: October 20, 2022

2.4K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Related Experiment Videos

Last Updated: Sep 27, 2025

Generation of a RIP1 Knockout U937 Cell Line Using the CRISPR-Cas9 System
08:15

Generation of a RIP1 Knockout U937 Cell Line Using the CRISPR-Cas9 System

Published on: April 11, 2025

462
Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells
09:15

Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells

Published on: October 20, 2022

2.4K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • Interferon signaling is implicated in resistance to immune checkpoint blockade (ICB) therapy.
  • The precise molecular mechanisms driving this resistance remain largely unknown.
  • Understanding these mechanisms is crucial for improving cancer immunotherapy efficacy.

Purpose of the Study:

  • To elucidate the role of interferon-stimulated genes in immunotherapy resistance.
  • To identify specific molecular players mediating resistance to ICB therapy.
  • To investigate the functional impact of identified genes on both intrinsic and extrinsic resistance.

Main Methods:

  • Analysis of interferon-stimulated genes in the context of ICB therapy.
  • Functional studies to assess the role of RIPK1 in immunotherapy resistance.
  • Investigation of RIPK1's effects on cell-extrinsic and cell-intrinsic resistance pathways.

Main Results:

  • Identification of Receptor-Interacting Protein Kinase 1 (RIPK1) as a key interferon-stimulated gene.
  • Demonstration that RIPK1 expression significantly contributes to immunotherapy resistance.
  • Evidence showing RIPK1 influences both cell-extrinsic and cell-intrinsic resistance mechanisms.

Conclusions:

  • RIPK1 is a critical mediator of interferon-driven resistance to immune checkpoint blockade.
  • Targeting RIPK1 may represent a novel strategy to overcome immunotherapy resistance.
  • Further research into RIPK1's role can inform the development of more effective cancer treatments.